Uridine triacetate (PN-401; RG 2133; Vistogard; Vistonuridine; Xuriden; Triacetyluridine; TAU), a prodrug of uridine, is an approved medication used for treatment of hereditary orotic aciduria or to treat patients following an overdose of chemotherapy drugs 5-fluorouracil or capecitabine. The acetyl groups of Vistonuridine increase the lipophilicity of uridine, thus enhancing its transport from the gastrointestinal tract to the blood stream and its reabsorption from the renal tubules, while rendering Vistonuridine resistant to catabolism by UrdPase. Uridine triacetate was granted breakthrough therapy designation by FDA in 2015. Uridine triacetate is a prodrug of uridine.

纯度：≥98%

CAS：4105-38-8